T. Rowe Price Associates’s LENZ Therapeutics LENZ Stock Holding History

T. Rowe Price Associates’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$416K	Buy	73,181 +33,560	+85%	+$271K	﹤0.01%	2702
2026 Q1	$364K	Sell	39,621 -983,921	-96%	-$13.8M	﹤0.01%	2580
2025 Q4	$16.4M	Buy	1,023,542 +772,411	+308%	+$22.5M	﹤0.01%	1110
2025 Q3	$11.7M	Buy	251,131 +236,198	+1,582%	+$8.69M	﹤0.01%	1189
2025 Q2	$438K	Sell	14,933 -292,045	-95%	-$7.94M	﹤0.01%	2366
2025 Q1	$7.89M	Sell	306,978 -515,979	-63%	-$12.7M	﹤0.01%	1155
2024 Q4	$23.8M	Buy	822,957 +374,326	+83%	+$11.4M	﹤0.01%	954
2024 Q3	$10.7M	Buy	+448,631	New	+$9.96M	﹤0.01%	1131

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

T. Rowe Price Associates's LENZ Position: Q2 2026 in Review

T. Rowe Price Associates increased its LENZ Therapeutics (LENZ) stake by 85% in Q2 2026, buying an estimated $271K and bringing the position to 73,181 shares worth $416K. The position accounts for ﹤0.01% of the portfolio, ranked #2702.

T. Rowe Price Associates first reported a position in LENZ in Q3 2024 and has held it in 8 quarters since. The position peaked at $23.8M in Q4 2024. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

T. Rowe Price Associates held 73,181 shares of LENZ Therapeutics worth $416K as of Q2 2026.
T. Rowe Price Associates bought 33,560 LENZ Therapeutics shares in Q2 2026, an estimated $271K.
LENZ Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2702 holding.
T. Rowe Price Associates first reported a position in LENZ Therapeutics in Q3 2024 and has held it in 8 quarters since.
T. Rowe Price Associates's LENZ Therapeutics position peaked at $23.8M in Q4 2024.
144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.